Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$28.97 USD
+0.88 (3.13%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $28.88 -0.09 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DNTH 28.97 +0.88(3.13%)
Will DNTH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Other News for DNTH
Baird starts Dianthus at outperform, cites lead drug DNTH103
Dianthus initiated with bullish view at Baird, here's why
Buy Rating on Dianthus Therapeutics Supported by Promising MMN Treatment Data and Market Potential
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
Dianthus initiated with bullish view at Cantor Fitzgerald, here's why